Vulnerabilities of PTEN-p53-deficient prostate cancers to compound PARP/PI3K inhibition

Prostate cancer (CaP) is the most prevalent cancer in males and treatment options are limited for advanced forms of the disease. Loss of the PTEN and p53 tumor suppressor genes is commonly observed in CaP, while their compound loss is often observed in advanced CaP. Here we show, that PARP inhibitio...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: González-Billalabeitia, Enrique, Seitzer, Nina, Song, Su Jung, Song, Min Sup, Patnaik, Akash, Liu, Xue-Song, Epping, Mirjam T., Papa, Antonella, Hobbs, Robin M., Chen, Ming, Lunardi, Andrea, Ng, Christopher, Webster, Kaitlyn A., Signoretti, Sabina, Loda, Massimo, Asara, John M., Nardella, Caterina, Clohessy, John G., Cantley, Lewis C., Pandolfi, Pier Paolo
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4125493/
https://ncbi.nlm.nih.gov/pubmed/24866151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0230
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki